Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07655180 · ClinicalTrials.gov registry record · Phase 3
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
A Phase 3 study, sponsored by Invivyd.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
NCT07655180 is a Phase 3 study that is actively recruiting participants, run by Invivyd. The registered enrollment target is 210 participants.
The verdict
NCT07655180, a Phase 3 study, is actively recruiting participants, sponsored by Invivyd.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
Study Summary
The main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in the body after receiving VYD2311, or a COVID-19 vaccine, or a combination of VYD2311 and a COVID-19 vaccine in healthy participants. This research study will measure the amount of serum virus neutralizing antibodies produced in the blood (antibodies that block a virus from infecting cells) and pharmacokinetics of VYD2311 compared to a COVID-19 vaccine, when each is administered alone or concurrently. Pharmacokinetics is the study of how a drug moves through the body, including how it is absorbed (taken into the body), distributed (spread throughout the body), metabolized (broken down in the body), and eliminated (removed from the body), and how the body affects the drug.
Interventions
- DRUG COVID-19 mRNA vaccine
- DRUG VYD2311
- DRUG Placebo (Normal Saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2026-06-08 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07655180
The ClinicalTrials.gov registry entry for NCT07655180 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invivyd, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which COVID-19 mRNA vaccine is the first listed.
NCT07655180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07655180 about?
NCT07655180 is a clinical study titled "Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine". The main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in the body after receivi...
What is the current status of trial NCT07655180?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2026-06-08. Estimated completion is 2026-08.
What interventions are being tested in trial NCT07655180?
The interventions under investigation include: COVID-19 mRNA vaccine (DRUG), VYD2311 (DRUG), Placebo (Normal Saline) (DRUG).
Who is sponsoring clinical trial NCT07655180?
This trial is sponsored by Invivyd, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.